1. What Is the Drug Eluting Stent Market?
The Drug Eluting Stent Market covers coated coronary and peripheral arterial stents that elute pharmacological agents locally to inhibit neointimal hyperplasia and reduce target lesion revascularization following percutaneous intervention. Interventional cardiologists and vascular interventionists implant Drug Eluting Stent devices at cardiac catheterization laboratories in patients with obstructive coronary artery disease and peripheral arterial stenosis who are candidates for percutaneous revascularization. The market includes everolimus-eluting, zotarolimus-eluting, and sirolimus-eluting cobalt-chromium coronary stents, sirolimus and paclitaxel-eluting peripheral stents for femoral popliteal disease, and bioresorbable vascular scaffold platforms that elute drug from a fully degradable polymer scaffold. Society for Cardiovascular Angiography and Interventions, ESC, and ACC/AHA guidelines on coronary revascularization define the indication framework for drug eluting stent use versus bypass surgery.
2. Drug Eluting Stent Market Size & Forecast
3. Emerging Technologies
- Everolimus-eluting cobalt-chromium coronary stents deliver antiproliferative drug from a polymer coating controlling release over 30 to 90 days, maintaining intimal hyperplasia suppression during the critical restenosis window following coronary intervention. Abbott's Xience and Boston Scientific's Promus family represent the market-leading everolimus-eluting coronary stent systems with the most extensive published long-term clinical outcome data.
- Ultrathin-strut sirolimus-eluting stents with strut thickness below 65 micrometers reduce flow disturbance and accelerate endothelial coverage, achieving lower rates of stent thrombosis and target vessel failure in randomized comparisons against thicker-strut predecessors. Biotronik's Orsiro and MedAlliance's Selution SLR represent the ultrathin and polymer-free sirolimus-eluting stent platforms advancing through regulatory approvals in multiple international markets.
- Drug-coated peripheral stents release paclitaxel or sirolimus locally at the femoral popliteal arterial wall to inhibit neointimal hyperplasia after balloon dilation, improving target lesion primary patency compared to bare metal stents in this high-restenosis segment. Cook Medical's Zilver PTX remains the most extensively studied peripheral drug eluting stent, with published five-year primary patency data in femoral popliteal disease.
- Bioresorbable polymer carrier technologies applied to metallic drug eluting stents provide controlled drug release through the peak restenosis period and then degrade, leaving a bare metal surface that reduces late polymer-related inflammatory reactions. Medtronic's Resolute Onyx and Terumo's Ultimaster use bioresorbable polymer systems on cobalt-chromium scaffolds as an intermediate design between durable polymer and fully bioresorbable scaffold approaches.
Similar technologies are also transforming adjacent markets. Learn more in our Peripheral Stent Market.
4. Key Market Opportunity
A key opportunity in the Drug Eluting Stent Market involves the continued penetration of drug eluting stents in emerging market cardiac catheterization programs across China, India, Brazil, and Southeast Asia, where bare metal stent use remains prevalent at mid-volume centers that have not upgraded to current-generation drug eluting products due to acquisition cost and reimbursement gaps. The growing femoral popliteal peripheral arterial disease revascularization market in aging populations across high-income countries is generating incremental procedure volume for peripheral drug eluting stent manufacturers as vascular interventionists transition from standard balloon angioplasty to drug eluting platforms with published patency advantages. Second-generation bioresorbable scaffold programs that successfully address first-generation thrombosis limitations represent a potential market renewal opportunity, as the clinical rationale for eliminating permanent metallic implant from the coronary artery remains intact for appropriate patient subgroups. The development of drug eluting stents for coronary bifurcation lesions, chronic total occlusion, and left main coronary disease represents advanced-indication expansion opportunities requiring dedicated stent design and procedural technique development.
5. Top Companies in the Drug Eluting Stent Market
The following organisations hold leading positions in the Drug Eluting Stent Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Abbott (Xience)
- Boston Scientific (Promus, Synergy)
- Medtronic (Resolute Onyx)
- Biotronik (Orsiro)
- Terumo (Ultimaster)
- Cook Medical (Zilver PTX)
- MedAlliance (Selution)
- Biosensors International (BioMatrix)
- Elixir Medical
- Lepu Medical
6. Market Segmentation
The Drug Eluting Stent Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Type | Everolimus Zotarolimus Sirolimus Biolimus Paclitaxel |
| By Scaffold Material | Metallic Cobalt-Chromium Biodegradable Polymer Bioresorbable Scaffold |
| By Application | Coronary Artery Disease Peripheral Arterial Disease |
| By End User | Hospitals and Cardiac Catheterization Centers Specialty Cardiovascular Hospitals |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Drug Eluting Stent Market trajectory over the forecast period:
Ultrathin Strut Drug Eluting Stents Are Demonstrating Improved Outcomes Gaining Adoption at High-Volume Interventional Cardiology Centers.Coronary stent strut thickness has decreased from over 150 micrometers in first-generation bare metal stents to less than 65 micrometers in current-generation thin-strut drug eluting platforms, with thinner struts demonstrating reduced flow disturbance and faster endothelialization. The BIOFLOW and TALENT randomized trials comparing ultrathin sirolimus-eluting stents against established comparators documented non-inferiority or superiority in target lesion failure rates, supporting US and European regulatory submissions. Biotronik's Orsiro ultrathin sirolimus-eluting stent and Medtronic's Onyx zotarolimus-eluting stent represent the current-generation thin-strut platforms achieving broad adoption at interventional cardiology programs. Interventional cardiologist adoption of ultrathin strut stents is driven by clinical training programs and favorable clinical evidence summaries in cardiology society continuing medical education.
Peripheral Drug Eluting Stents Are Gaining Market Share Over Bare Metal Stents in Femoral Popliteal Disease.Femoral popliteal arterial disease is characterized by high restenosis rates with standard balloon angioplasty due to repetitive flexion forces on the stented segment, and drug eluting stent technology has been adapted to address this biomechanical challenge. The EMINENT randomized trial and registry data from the Zilver PTX sirolimus-eluting stent program documented improved 12-month target lesion primary patency compared to bare metal stent controls in femoral popliteal lesions. Cook Medical's Zilver PTX paclitaxel polymer-free drug eluting peripheral stent has been the market leader in peripheral drug eluting stenting with broad US and international regulatory approvals. Newer sirolimus-eluting peripheral stents are competing for femoral popliteal procedural share as vascular interventionists increase peripheral stenting volumes in aging populations.
Bioresorbable Vascular Scaffold Technology Is Advancing Through a Second-Generation Design Era After First-Generation Thrombosis Setbacks.The initial enthusiasm for bioresorbable vascular scaffolds was dampened when the 2016 and 2017 ABSORB II and III trial data showed higher scaffold thrombosis rates than metallic drug eluting stents at three-year follow-up. Abbott voluntarily withdrew the ABSORB scaffold in 2017, and subsequent analysis identified thick struts and incomplete lesion preparation as primary contributors to the thrombosis signal, guiding second-generation redesign programs. Second-generation programs from Elixir Medical and Amaranth Medical incorporate ultrathin struts and improved polymer formulations to address first-generation safety limitations. The bioresorbable scaffold segment remains in clinical development with commercial relaunch expected pending successful pivotal trial completion.
For related market intelligence, see the Coronary Stent Market.
8. Segmental Analysis
By drug type, the Everolimus-Eluting Stents segment dominated the Drug Eluting Stent Market in 2025, representing the established standard-of-care coronary stent platform at high-volume interventional cardiology programs globally, with Abbott's Xience and Boston Scientific's Promus family maintaining the largest US and international regulatory approvals and clinical data libraries. The Sirolimus-Eluting Ultrathin Strut Stents segment is the fastest-growing drug type category, gaining market share as Biotronik's Orsiro and similar ultrathin platform data demonstrate comparable or superior outcomes to established everolimus stents in randomized trials and registries.
By application, Coronary Artery Disease led overall market revenue, while Peripheral Arterial Disease is registering the highest growth rate as drug eluting peripheral stent adoption expands in femoral popliteal revascularization programs replacing standard bare metal protocols.
9. Regional Analysis
Regional demand patterns across the Drug Eluting Stent Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Drug Eluting Stent Market in 2025, accounting for approximately ~38% of global market revenue, driven by high percutaneous coronary intervention procedure volumes, established interventional cardiology infrastructure at comprehensive cardiac care hospitals, and the commercial leadership of Abbott and Boston Scientific in the coronary drug eluting stent segment. Moreover, CMS reimbursement for percutaneous coronary intervention with drug eluting stent implantation provides financial justification for current-generation stent procurement at hospital cardiac catheterization laboratory accounts. In addition, active FDA engagement on new stent design clearances and the concentration of high-enrollment clinical trials at US academic cardiac centers sustains product innovation cycles in the North American drug eluting stent market. The established intervention volume, reimbursement structure, and innovation infrastructure sustain North American leadership in the Drug Eluting Stent Market through the forecast period.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Drug Eluting Stent Market through 2034, advancing at approximately ~12.5%, driven by high and rising cardiovascular disease burden across China, India, and Southeast Asia, expanding cardiac catheterization laboratory capacity at urban hospitals, and growing government health insurance coverage for percutaneous coronary intervention enabling drug eluting stent access for previously price-limited patient populations. The region benefits from large domestic coronary stent manufacturing in China and India, where regulatory-approved domestic drug eluting stent brands compete on price with international products at government hospital procurement programs. Moreover, the transition from bare metal to drug eluting stenting at mid-volume interventional cardiology centers in China, India, and Vietnam represents a multi-year market upgrade cycle generating consistent per-unit volume growth. The combination of cardiovascular disease burden, catheterization capacity expansion, and domestic product competition positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Drug Eluting Stent Market was valued at USD 8.47 Bn in 2025 and is projected to reach USD 19.02 Bn by 2034, growing at a CAGR of 9.4% over the 2026–2034 forecast period.
The Drug Eluting Stent Market is projected to grow at a CAGR of 9.4% from 2026 to 2034.
North America dominated the Drug Eluting Stent Market in 2025, accounting for approximately ~38% of global market revenue, driven by high percutaneous coronary intervention procedure volumes, established interventional cardiology infrastructure at comprehensive cardiac care hospitals, and the commercial leadership of Abbott and Boston Scientific in the coronary drug eluting stent segment.
The leading companies in the Drug Eluting Stent Market include Abbott (Xience), Boston Scientific (Promus, Synergy), Medtronic (Resolute Onyx), Biotronik (Orsiro), Terumo (Ultimaster), Cook Medical (Zilver PTX), MedAlliance (Selution), Biosensors International (BioMatrix), Elixir Medical, Lepu Medical.
Ultrathin strut drug eluting stents are demonstrating improved outcomes gaining adoption at high-volume interventional cardiology centers.
By drug type, the Everolimus-Eluting Stents segment dominated the Drug Eluting Stent Market in 2025, representing the established standard-of-care coronary stent platform at high-volume interventional cardiology programs globally, with Abbott's Xience and Boston Scientific's Promus family maintaining the largest US and international regulatory approvals and clinical data libraries.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.